COMMUNIQUÉS West-GlobeNewswire

Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
20/05/2026
Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically “cold” tumors [...]
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
20/05/2026
PETACH TIKVA, Israel, May 20, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment [...]
Stablecoin Development Corporation Reports First Quarter 2026 Financial Results
20/05/2026
Company Generated $22.3 Million of Operating Income and Reported $552.4 Million of GAAP Net Income, Including Significant Non-Cash Warrant-Related Gains Company Held Approximately 2.15 Billion SKY Tokens at March 31, [...]
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
20/05/2026
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive [...]
Vistin Pharma ASA: Minutes from the annual general meeting 2026
20/05/2026
Oslo, Norway, 20 May 2026 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 20 May 2026. Attachment Minutes from AGM Vistin Pharma ASA_20_May_2026
Sustainability Leader Ashley McKeon Selected as Soil Health Institute’s President and CEO
20/05/2026
MORRISVILLE, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Ashley McKeon, a seasoned agriculture and sustainability executive, will lead the Soil Health Institute (SHI) into its next decade. McKeon, who previously led [...]
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
20/05/2026
TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“ PharmAla ” or the “ Company ”), a global leader in the research, development, and manufacturing of novel MDXX-class [...]
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
20/05/2026
31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstracts Independent [...]
Glass House Brands to Host Investor Sesh V on Thursday, June 18, 2026
20/05/2026
Company to Hold its Fifth Annual ‘Investor Sesh’ in Appreciation of Investor Support and in Commitment to Transparency for Shareholders LONG BEACH, Calif. and TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- Glass House Brands [...]
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
20/05/2026
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq ® technology, marking a [...]
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
20/05/2026
Multi-year partnership lands as Prenetics’ IM8 raises full-year 2026 revenue guidance to $190 million to $210 million following nearly 6x year-over-year growth in Q1 2026 Shetty is IM8’s first global ambassador from [...]
C4 Therapeutics to Participate in Upcoming Conferences
20/05/2026
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
Medline Inc. announces launch of secondary offering of Class A common stock
20/05/2026
NORTHFIELD, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., Hellman & Friedman LLC and a wholly owned [...]
Syndax Announces Participation in Upcoming Investor Conferences
20/05/2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief [...]
NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting
20/05/2026
Company to participate in plenary panel on artificial intelligence in psychiatry and present two scientific posters highlighting explainable AI applications in precision psychiatry TORONTO, May 20, 2026 (GLOBE NEWSWIRE [...]
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
20/05/2026
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that [...]
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
20/05/2026
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases [...]
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
20/05/2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will [...]

Pages